Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05393869
Other study ID # OSU-20427
Secondary ID NCI-2022-02543K9
Status Completed
Phase N/A
First received
Last updated
Start date April 14, 2021
Est. completion date November 14, 2022

Study information

Verified date December 2023
Source Ohio State University Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial refines and evaluates anti-tobacco messages among lesbian, gay, bisexual, and transgender (LGBT) young adults at risk for the use of more than one tobacco product (polytobacco use). Polytobacco use is associated with nicotine dependence and tobacco use into adulthood, and is disproportionately high among LGBT young adults. This trial seeks to determine effective communication of polytobacco use risk to at-risk LGBT young adults.


Description:

PRIMARY OBJECTIVES: I. Identify absolute and relative risk anti-tobacco messages that effectively communicate polytobacco risks to lesbian, gay, bisexual, transgender (LGBT) young adults. Participants view anti-tobacco messages and rate them for perceived effectiveness and reactance.


Recruitment information / eligibility

Status Completed
Enrollment 2849
Est. completion date November 14, 2022
Est. primary completion date November 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Young adults (age 18-35 years) - Live in the United States At least 50% of the sample also: - Are susceptible to multiple nicotine and tobacco product use (i.e., have used combustible tobacco or e-cigarettes at least once)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Health communications
Participants are assigned to view health communications with risk and efficacy statements.

Locations

Country Name City State
United States Ohio State University Comprehensive Cancer Center Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Ohio State University Comprehensive Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Message Perceived Effectiveness - Persuasive Potential. 6 items measured on 5-point scale, 1 = Not at all and 5 = Very much
These messages were worth remembering.
These messages grabbed my attention.
These messages are powerful.
These messages are convincing.
These messages are meaningful.
These messages are informative.
Responses were summed and averaged to create a scale for intention to quit (range from 1 - 5).
Higher scores indicate a higher persuasive potential of the message.
Immediately post-exposure to intervention, up to 1 hour
Primary Perceived Effectiveness - Perceived Behavioral Impact Six items were analyzed separately, each scored on 5-point Likert scale (1=Strongly Disagree, 5=Strongly Agree)
These messages will motivate CIGARETTE SMOKERS to switch to vaping.
These messages will motivate people to quit ALL smoking and vaping.
These messages will motivate NON-USERS to start vaping.
These messages will motivate NON-USERS to start smoking cigarettes.
These messages will motivate CIGARETTE SMOKERS to quit.
These messages will motivate VAPERS to quit.
Immediately post-exposure to intervention, up to 1 hour
Primary Risk Perceptions: Absolute/Relative Risks of Cigarette vs. E-cigarette Use On a scale from 0-10, where 0 = not at all harmful and 10 = extremely harmful now harmful are ... to your health?
combustible cigarettes
nicotine vapes
On a scale from 0-10, where 0 = much less harmful and 10 = much more harmful...
• compared to combustible cigarettes, how harmful are nicotine vapes to your health?
Immediately post-exposure to intervention, up to 1 hour
Primary Behavioral Intentions to Use Tobacco 8-items made up two 4-pt scales (1 = definitely will not and 4 = definitely will).
Items for each scale were summed and averaged. Higher scores indicate higher likelihood of avoiding cigarettes/nicotine vapes.
How likely it is that in the next 3 months, you will refrain from...
smoking cigarettes completely and permanently?
smoking cigarettes when you get lonely?
smoking cigarettes when you are with your friends who use them?
smoking cigarettes when someone hands you a cigarette?
How likely it is that in the next 3 months, you will refrain from...
vaping nicotine completely and permanently?
vaping nicotine when you get lonely?
vaping nicotine when you are with your friends who use them?
vaping nicotine when someone hands you a vape?
Immediately post-exposure to intervention, up to 1 hour
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06315881 - Informing Oral Nicotine Pouch Regulations to Promote Public Health Phase 2
Active, not recruiting NCT02964182 - Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers N/A
Completed NCT04267874 - Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study Early Phase 1
Completed NCT04510077 - SmartQuit Program for Smoking Cessation N/A
Completed NCT03200236 - The Lung Screening, Tobacco and Health Project Phase 3
Recruiting NCT05730439 - Examining the Impact of Nicotine Pouches in Rural Ohio and Ohio Appalachia Early Phase 1
Recruiting NCT04949464 - Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study N/A
Not yet recruiting NCT06249984 - Effects of Tobacco Cut and Nicotine Form on the Abuse Liability of Moist Snuff N/A
Enrolling by invitation NCT04969978 - Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation N/A
Completed NCT05972941 - Nicotine and Tobacco Message Framing Among LGBT Young Adults N/A
Completed NCT05453773 - Hookah Additive Research to Inform Product Standards N/A
Withdrawn NCT05411107 - Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Phase 2
Completed NCT03268993 - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer N/A
Recruiting NCT04340531 - Effectiveness of a Multi-Level Smoking Cessation Program for High-Risk Women in Rural Communities Phase 4
Terminated NCT04297332 - Episodic Future Thinking and Future Thinking Priming for Smoking Cessation N/A
Completed NCT03402230 - Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers Early Phase 1
Recruiting NCT05679349 - Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking N/A
Recruiting NCT05876091 - Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography N/A
Completed NCT03182959 - Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer Early Phase 1

External Links